이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Prospective, Multicenter, Randomized, No-Treatment Controlled, Evaluator-Blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of a Medical Collagen Filler for Correcting Infraorbital Depression

Infraorbital hollowing, also known as tear trough deformity, refers to a sunken groove extending from the medial canthal region along the infraorbital rim downward and laterally. It is one of the key features of facial aging and remains one of the most challenging issues in periorbital rejuvenation [1,2]. This deformity is particularly common among Asian populations, with approximately 60%-70% of middle-aged individuals presenting with varying degrees of infraorbital hollowing [2]; its incidence increases significantly with age. The formation of infraorbital hollowing results from the combined effects of multiple factors, including anatomical changes, soft tissue atrophy, skin aging, and impaired lymphatic circulation [2]. Beyond compromising facial aesthetics, it creates negative impressions of fatigue, aging, and sternness, which can severely affect patients' psychological well-being and social lives [3]. In recent years, driven by growing demand for facial rejuvenation, infraorbital hollowing correction has become a popular non-surgical aesthetic procedure.

However, due to the complex anatomy of the infraorbital region-characterized by thin skin, abundant vasculature, and fragile lymphatic drainage-traditional fillers are prone to issues such as migration, the Tyndall effect, and prolonged swelling, placing higher demands on both filling materials and injection techniques [4]. Collagen, as a natural biomaterial, offers distinct advantages for infraorbital hollowing correction owing to its excellent biocompatibility, low migration tendency, and light-scattering properties [5]. The mechanism of collagen injection for infraorbital hollowing correction is a complex, multi-stage, and multi-level process that achieves immediate physical volumization and tissue support. Injected collagen replenishes lost volume, forming a soft, cohesive fibrous structure that lifts the depressed area and restores a smooth transition between the lower eyelid and cheek, thereby reducing the hollowed appearance [5,6]. Meanwhile, due to its high adhesiveness, collagen binds loosened skin tissues together, repositions the disrupted fibrous scaffold network, and restores a youthful, firm contour [6]. After injection, the collagen gradually dehydrates and condenses, reorganizing into a fibrillar structure resembling native collagen in vivo, which further tightens tissues and enhances the supporting effect.

The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. was approved for marketing by the NMPA in 2016 (Registration Certificate No.: Guo Xie Zhu Zhun 20163131609). It is indicated for dermal filling of the face to correct moderate to severe nasolabial folds, and has demonstrated favorable efficacy and safety in clinical practice. The proposed new indication is infraorbital filling for the improvement and correction of infraorbital hollowing. The objective of this study is to evaluate the efficacy and safety of this medical collagen filler manufactured by Feifan (Changchun) Medical Biotechnology Co., Ltd. in correcting the severity of infraorbital hollowing. In accordance with the Measures for the Administration of Medical Device Registration and Filing, the Good Clinical Practice for Medical Device Clinical Trials (GCP), and the Guidelines for Medical Device Clinical Trial Design, and adhering to the ethical principles of the World Medical Association Declaration of Helsinki, this study strives to maximize benefits for research participants while minimizing potential harm.

연구 개요

상태

아직 모집하지 않음

연구 유형

중재적

등록 (추정된)

171

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged 18 years or older (based on the time of signing the informed consent form), of any gender; Assessed by the blinded investigator, both eyes must exhibit moderate to severe infraorbital hollowing (i.e., an Allergan Infraorbital Hollowing Scale [AIHS] grade of 2-3), and the participant must desire improvement in the infraorbital hollowing; Able to complete the efficacy self-assessment without wearing framed glasses (wearing contact lenses for self-assessment is acceptable); Able and willing to follow the investigator's instructions, comply with the treatment restrictions specified in this protocol, and attend all scheduled study visits; Voluntarily participating in this clinical trial and signing the research participant informed consent form.

Exclusion Criteria:

  • 1. Known allergy to collagen, any component of the investigational product, or any local anesthetic (e.g., lidocaine or other amide-type anesthetics); 2. History of severe allergic reactions (e.g., anaphylactic shock, laryngeal edema, asthma, dyspnea, hypotension, syncope shortly after exposure to an allergen); 3. Presence of scars, deformities, unhealed wounds, or other conditions in the planned injection area and bilateral midface that may interfere with efficacy evaluation or increase treatment risk, potentially compromising visual assessment of the infraorbital rim, or active/recurrent inflammation or infection in either eye; 4. Previous treatment with any permanent filler (e.g., polymethylmethacrylate [PMMA], silicone, expanded polytetrafluoroethylene [ePTFE]), autologous fat, or unknown injectables in the planned injection area and bilateral midface; 5. Treatment with poly-L-lactic acid (PLLA), polycaprolactone (PCL), calcium hydroxylapatite (CaHA), or similar agents in the planned injection area and bilateral midface within 24 months prior to screening or planned during the trial period; 6. Treatment with cross-linked sodium hyaluronate, animal-derived collagen, or similar agents in the planned injection area and bilateral midface within 12 months prior to screening or planned during the trial period; 7. Treatment with recombinant human-like collagen, botulinum toxin, or similar agents in the planned injection area and bilateral midface within 6 months prior to screening or planned during the trial period; 8. History of active autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis); 9. Treatment with non-cross-linked sodium hyaluronate filler or cosmetic procedures (e.g., intense pulsed light [IPL], radiofrequency, dermabrasion, laser, chemical peels) in the planned injection area and bilateral midface within 6 months prior to screening; 10. Previous lower blepharoplasty or facial lift/brow lift within 12 months prior to screening; 11. In the investigator's judgment, presence of large lower eyelid fat pads affecting treatment or excessive pigmentation in the infraorbital area (excluding dark circles not caused by hyperpigmentation); 12. History of keloids or keloid-prone constitution (hypertrophic scarring tendency); 13. Chemotherapy, immunosuppressants, immunomodulatory therapy (e.g., monoclonal antibodies), or systemic corticosteroids (except inhaled corticosteroids) within 3 months prior to screening; 14. Screening liver function tests showing ALT and/or AST > 2 × upper limit of normal (ULN), or renal function tests showing Cr > 1.5 × ULN, and deemed by the investigator as unsuitable for the trial; 15. History of bleeding disorders (e.g., porphyria, coagulation factor deficiency, coagulopathy, or platelet disorders); clinically significant abnormal coagulation function at screening (e.g., APTT > 1.5 × ULN); or receipt of anticoagulant, antiplatelet, or thrombolytic therapy (e.g., warfarin, heparin, aspirin) within 2 weeks prior to screening; 16. In the investigator's judgment, severe dysfunction of vital organs (e.g., brain, heart, lung, liver, kidney), such as severe cardiovascular or cerebrovascular diseases (hospitalization for myocardial infarction or cardiac surgery, congestive heart failure, or myocardial infarction within 3 months; severe unstable arrhythmia; hypertrophic cardiomyopathy; severe aortic stenosis; aneurysm; stroke), severe pulmonary diseases (moderate to severe pneumonia, respiratory failure), or uncontrolled diabetes; 17. Epilepsy, mental disorders, or other severe neuropsychiatric conditions that may preclude completion of trial follow-up; 18. Lactating women or those planning pregnancy during the study period; 19. Participation in another interventional clinical trial within 1 month prior to screening; 20. Any other condition that, in the investigator's opinion, makes the participant unsuitable for this clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Varying degrees of Infraorbital Depression

The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores
기간: 3 months after the last injection in the experimental group and at 3 months after randomization in the control group

The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores at 3 months after the last injection in the experimental group and at 3 months after randomization in the control group, as evaluated by blinded investigator

3 months after the last injection in the experimental group and at 3 months after randomization in the control group

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 25일

기본 완료 (추정된)

2027년 7월 25일

연구 완료 (추정된)

2028년 7월 25일

연구 등록 날짜

최초 제출

2026년 11월 13일

QC 기준을 충족하는 최초 제출

2026년 11월 18일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 18일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • FimanPharma-Xuanwu Hospital

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다